Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 0.76 |
| ▸ | AR | P10275 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone SCHEMBL14135286 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL2231799 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL4069 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL28888601 | 0.99 | NR3C1 (0.98) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL28821706 | 0.99 | NR3C1 (0.98) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL28935320 | 0.98 | NR3C1 (0.97) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL27674669 | 0.97 | NR3C1 (0.95) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL896670 | 0.97 | NR3C1 (0.93) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL29113054 | 0.96 | NR3C1 (0.92) | NR3C1PGRARCYP3A4HIF1A | |
| Fluticasone SCHEMBL3365958 | 0.95 | NR3C1 (0.91) | NR3C1PGRARCYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108730-A1 | CORTICOSTEROID COMPOSITIONS | VIROPHARMA BIOLOGICS LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230218630-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | ALKEM LABORATORIES LIMITED (IN) | 2023-07-13 | — | — | US | disclosed |
| US-11357859-B2 | Compositions for the treatment of gastrointestinal inflammation | VIROPHARMA BIOLOGICS LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200345842-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-05 | — | — | US | disclosed |
| EP-3701941-A1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | Flexion Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10675602-B2 | Spray-drying process | BEND RESEARCH, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-2600836-B1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | FLEXION THERAPEUTICS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10624905-B2 | Corticosteroids for the treatment of joint pain | FLEXION THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190262791-A1 | SPRAY-DRYING PROCESS | BEND RESEARCH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-10370402-B2 | Process for the preparation of fluticasone propionate form 1 | PFIZER LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-20090131386-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | MERITAGE PHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090123550-A1 | CORTICOSTEROID COMPOSITIONS | MERITAGE PHARMA, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090123390-A1 | COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION | MERITAGE PHARMA, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1893161-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND COOLING AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | Symrise GmbH & Co. KG (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134120-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND COOLING AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060051300-A1 | Formulations and methods for treating rhinosinusitis | MERCK PATENT GMBH | 2006-03-09 | — | — | US | disclosed |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050180925-A1 | powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; comprise an antifungal agent, antibiotic or antiviral agent; fungus-induced rhinosinusitis | DEY, L.P. | 2005-08-18 | — | — | US | disclosed |
| US-20040209852-A1 | Fluticasone powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; comprise an antifungal agent, antibiotic or antiviral agent; fungus-induced rhinosinusitis | MYLAN SPECIALTY L.P. | 2004-10-21 | — | — | US | disclosed |
| US-20040208830-A1 | Nasal pharmaceutical formulations and methods of using the same | MYLAN SPECIALTY L.P. | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108730-A1 | CORTICOSTEROID COMPOSITIONS | NR3C1, SERPINA6, NR3C2 | NR3C1 1/4885PGR 580/4885AR 637/4885 |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | CYP17A1, CYP21A2, SHBG | NR3C1 45/4885PGR 211/4885AR 26/4885 |
| US-20090123550-A1 | CORTICOSTEROID COMPOSITIONS | NR3C1, SERPINA6, NR3C2 | NR3C1 1/4885PGR 580/4885AR 637/4885 |
| US-20090123390-A1 | COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION | FABP2, FABP6, FABP1 | NR3C1 342/4885PGR 2390/4885AR 4601/4885 |
| US-20040208830-A1 | Nasal pharmaceutical formulations and methods of using the same | NR3C1, MC2R, NR3C2 | NR3C1 1/4885PGR 423/4885AR 182/4885 |
| US-10370402-B2 | Process for the preparation of fluticasone propionate form 1 | CYP4A11, NR5A1, CYP2F1 | NR3C1 87/4885PGR 1000/4885AR 647/4885 |
| US-10624905-B2 | Corticosteroids for the treatment of joint pain | CRH, NR3C1, MC2R | NR3C1 2/4885PGR 350/4885AR 447/4885 |
| US-20090131386-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | FABP2, FABP6, PTGES2 | NR3C1 257/4885PGR 2120/4885AR 4445/4885 |
| US-20230218630-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | CCL11, IL5, TSLP | NR3C1 9/4885PGR 1361/4885AR 84/4885 |
| US-11357859-B2 | Compositions for the treatment of gastrointestinal inflammation | FABP2, FABP6, TNF | NR3C1 341/4885PGR 2365/4885AR 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.